Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect

Molecular Cancer Therapeutics

Volumn 3, Issue 2, 2004, Pages 169-178

  Hayward, Richard L ^a   Macpherson, Janet S ^a   Cummings, Jeff ^a   Monia, Brett P ^b   Smyth, John F ^a   Jodrell, Duncan I ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL STRAIN; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TARGETING; GENETIC ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IN VIVO STUDY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, ANTISENSE; DOWN-REGULATION; GENOTYPE; HCT116 CELLS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444375998     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol, 1998;25:4-12.
2. Shirota Y, Stoehimacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 2001;19:4298-304.
3. Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry, 1999;38:11026-39.
4. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res, 1998;58: 3579-85.
5. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res, 1996;56:4881-6.
6. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell, 2002;9:175-86.
7. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature, 1999;399:806-9.
8. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res, 2001;61:1508-16.
9. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 1999;104:263-9.
10. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol, 1998;8:345-57.
11. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res, 1997;3:1653-60.
12. te Poele RH, Joel SP. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer, 1999;81:1285-93.
13. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature, 1999;401:616-20.
14. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev, 2000;14:1584-8.
15. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell, 2001;7: 673-82.
16. Lutz RJ. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem Soc Trans, 2000;28:51-6.
17. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem, 1997;272:24101-4.
18. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature, 1994;369:321-3.
19. Reed JC. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt, 1996;72-100.
20. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol, 1998;16:395-419.
21. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res, 1999;59:1693s-1700s.
22. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science, 2000;290:989-92.
23. Gourdier I, Del Rio M, Crabbe L, et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett, 2002;529:232-6.
24. Chipuk JE, Bhat M, Hsing AY, Me J, Danielpour D. Bcl-xL blocks transforming growth factor-β 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem, 2001;276:26614-21.
25. Crescenzi E, Criniti V, Pianese M, Tecce MF, Palumbo G. Differential expression of antiapoptotic genes in human endometrial carcinoma: bcl-XL succeeds bcl-2 function in neoplastic cells. Gynecol Oncol, 2000; 77:419-28.
26. Fernandez Y, Espana L, Manas S, Fabra A, Sierra A. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ, 2000;7:350-9.
27. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene, 2000;19:5477-86.
28. Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res, 2000;60:3051-7.
29. Cherbonnel-Lasserre C, Gauny S, Kronenberg A. Suppression of apoptosis by Bcl-2 or Bcl-xL promotes susceptibility to mutagenesis. Oncogene, 1996;13:1489-97.
30. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene, 1995;11:1389-94.
31. Amundson SA, Myers TG, Scudierc, D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res, 2000;60:6101-10.
32. Flohil CC, Janssen PA, Bosman FT. Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol, 1996;178:393-7.
33. Bosari S, Moneghini L, Graziani D, et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol, 1995;26:534-40.
34. Yao T, Kajiwara M, Kouzuki T, Iwashita A, Tsuneyoshi M. Villous tumor of the colon and rectum with special reference to roles of p53 and bcl-2 in adenoma-carcinoma sequence. Pathol Int, 1999;49:374-82.
35. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res, 1996;56:2422-7.
36. Maurer CA, Friess H, Buhler SS, et al. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci, 1998;43:2641-8.
37. Hirose Y, Yoshimi N, Suzui M, Kawabata K, Tanaka T, Mori H. Expression of bcl-2, bax, and bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas. Mol Carcinog, 1997;19:25-30.
38. Saleh HA, Jackson H, Banerjee M. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol, 2000;8:175-82.
39. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res, 1995;1:1103-10.
40. Nita ME, Ono-Nita SK, Tsuno N, et al. Bcl-X (L) antisense sensitizes human colon cancer cell line to 5-fluorouracil. Jpn J Cancer Res, 2000;91:825-32.
41. Strasberg Rieber M, Zangemeister-Wittke U, Rieber M. p53-independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res, 2001;7:1446-51.
42. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res, 2000;6:2547-55.
43. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer, 2000;86:855-62.
44. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst, 2001;93:463-71.
45. Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE. In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukemia cell death in a SCID/NOD-Hu model. Br J Haematol, 2001;112:706-13.
46. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000;60:6052-60.
47. Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta, 1999;1489:97-106.
48. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol, 2000;18:1812-23.
49. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet, 2000;356: 1728-33.
50. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol, 1999;17:1364-74.
51. Schelwies K, Sturm I, Grabowski P, et al. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer, 2002;99:589-96.
52. 2 arrest after DNA damage. Science, 1998;282:1497-501.
53. Steel GG. Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys, 1979;5:85-91.
54. Whitacre CM, Zborowska E, Willson JK, Berger NA. Detection of poly (ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clin Cancer Res, 1999;5:665-72.
55. Gayet J, Zhou XP, Duval A, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene, 2001;20:5025-32.
56. Kern W, Braess J, Bottger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res, 1999;5:761-5.
57. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res, 2000;6:1205-18.
58. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA, 1999;96:14517-22.
59. Merchant AK, Loney TL, Maybaum J. Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells. Oncogene, 1996;13:2631-7.
60. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature, 1997;385: 637-40.
61. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA, 2000;97:10872-7.
62. Agrawal S, Kandimalla ER, Yu D, et al. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. Int J Oncol, 2001;18:1061-9.
63. Degterev A, Lugovskoy A, Cardona M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol, 2001;3:173-82.
64. Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol, 2001;3:183-91.
65. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 2002;109:335-46.